Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Amicus Therapeutics: Regulatory Update And Financing Add To Bull Case

12h seekingalpha
Shares have come a long way since my original recommendation and are currently trading about 10% under the 52-week high. (23-1)

Shire PLC 2017 Q4 - Results - Earnings Call Slides

2018-02-14 seekingalpha
The following slide deck was published by Shire PLC in conjunction with their 2017 Q4 earnings call. (3-0)

Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis

2018-02-08 seekingalpha
Pompe market opportunity appears attractive with 5,000 to 10,000 patients worldwide and 2016 global ERT sales reaching nearly $800 million. (19-0)

SHPG / Shire Plc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-30 fintel.io
Shire Plc. (NASDAQ:SHPG) has 499 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 132,950,961 shares. Largest shareholders include BlackRock Inc., Glenview Capital Management, Llc, Price T Rowe Associates Inc /md/, Paulson & Co. Inc., UBS Group AG, FMR LLC / Fidelity, Maverick Capital Ltd, Manufacturers Life Insurance Company, The, Invesco Ltd. (39-0)

Insiders Are Buying At 2 Attractive Biotechs

2018-01-19 seekingalpha
I have always found a strong correlation between insider buying and upside potential in the biotech sector. (121-6)

Ascend Pharma: This ROTY Contender Continues To Execute

2018-01-18 seekingalpha
Recent updates on their clinical programs reveal that management is doing a solid job of executing on pipeline initiatives. (3-0)

What Went Wrong For Shire In 2017 And Why 2018 Will Be Different

2017-12-31 seekingalpha
Current valuation is really attractive because it doesn't reflect the leading position of Shire in the Rare Disease franchise. (3-1)

Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

2017-12-28 zacks
Protalix BioTherapeutics, Inc. (PLX - Free Report) announced that the European Commission (“EC”) has granted orphan drug designation to its pipeline candidate, PRX-102 (pegunigalsidase alfa). The small biotech company is developing PRX-102 for patients with Fabry disease, a rare inherited genetic lysosomal disorder. (78-1)

What Shire Is Planning With Its Newest FDA Submission

2017-12-27 247wallst
Although Shire PLC (NASDAQ: SHPG) is not seeing much of a bump in its share price, the firm is creating a lot of value with its most recent submission to the U.S. Food and Drug Administration (FDA). According to the firm, it entered its first submission to the FDA for the company`s new plasma manufacturing facility in Covington, Georgia. (3-0)

Shire: 2018 May Be A Year Of Positive Changes

2017-12-27 seekingalpha
Shire Plc (NASDAQ:SHPG) was facing what some considered an existential threat from Roche’s (OTCQX:RHHBY) ACE910, brand name emicizumab, market name after approval Hemlibra. This drug was a direct challenge to Shire’s dominance in the $11bn Hemophilia market. ACE910 is a subcutaneous prophylaxis for adults, children, and adolescents with haemophilia A with factor VIII inhibitors. In the HAVEN trial, the drug showed a 87% reduction in bleed rate in patients who had developed resistance to standard treatment, compared with those who instead received so-called bypassing agents that are currently used as standard therapy. (3-0)

Glenview Capital Management, Llc - All Holdings - 13F 13D 13G Filings - Fintel.io

2017-12-26 fintel.io
Glenview Capital Management, Llc has disclosed 56 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 17,234,823,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Glenview Capital Management, Llc's top holdings are HCA Holdings Inc. (NYSE:HCA) , Dow Chemical Co. (The) (NYSE:DOW) , FMC Corp. (NYSE:FMC) , Shire Plc. (60-0)

Shire (SHPG) a Sell on Sagging Quant Score

2017-12-12 investorplace
Currently, Shire plc (NASDAQ:SHPG) has a Sell using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. SHPG has maintained this ranking for 11 months. (3-0)

Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology

2017-12-07 accesswire
LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors issued a free report on Shire PLC (NASDAQ: SHPG), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=SHPG as the Company's latest news hit the wire. On December 05, 2017, the Company declared that it has entered into a collaboration with Rani Therapeutics to exclusively conduct research on the use of the Rani Pill(TM) technology for the oral delivery of factor VIII (FVIII) therapy, for delivering treatment to patients with hemophilia A. (32-0)

Lousy Quant Score Make Shire (SHPG) a Sell

2017-12-05 investorplace
Shire plc (NASDAQ:SHPG) is a constituent of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. SHPG's market value is $44.8 billion which places it in the top 10% of its industry group. The current Portfolio Grader ranking for SHPG puts it 233 among the 350 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 538 among the 782 companies in the sector, and number 3,229 in the nearly 5,000 company Portfolio Grader universe. (3-0)

Your Daily Pharma Scoop: Dynavax Beyond Heplisav-B, Novartis' Cosentyx, Shire Granted ODD

2017-12-01 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (155-0)

CUSIP: 82481R106